Identifying and Cloning Neoepitope Specific, CD4+ T Cells from Newly Diagnosed Glioma Patients in a Phase I Vaccination Trial Targeting Mutant IDH1 Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse gliomas, and in previous work we showed that vaccinating mice with an IDH1.R132H-specific peptide induced tumor-specific therapeutic T helper cell responses and subsequent tumors control. In a multicenter, single-arm, open-label, first-in-man phase I trial involving vaccinating 33 patients with grade 3 and 4 IDH1.R132H+ve astrocytomas we were able to show vaccine-induced immune responses in 93.3 % of patients. By combining scRNA- and T cell receptor (TCR)-sequencing, we were able to identify and clone TCRs from patients, and have gone on to show that these are IDH1.R132H reactive. These results provide new hope for patients with IDH1.R132H mutated brain tumours, and point towards future applications of such TCRs in (personalised) adoptive cell therapies.

Discover how the synthetic advantage can streamline your discovery efforts with Twist Antibody Libraries. Twist Bioscience capitalizes on its massively parallel DNA synthesis platform to generate custom antibody libraries that meet your needs. Complementing this service is the Library of Libraries, a collection of synthetic antibody libraries offered off-the-shelf by Twist Biopharma, a division of Twist Bioscience. Every ready-to-use library offers unique, drug-like antibodies and comes with advanced design support from Twist Biopharma. Compared to those from immunized sources, Twist Antibody Libraries are more diverse, cost-effective, and faster to obtain, making antibody discovery easier than ever before.

Twist's proprietary oligo synthesis technology offers a unique approach to library creation with silicon-based synthesis platform that generates high-quality oligo pools, which are used to build fully-customized, user-defined variant libraries on a single chip.